[Federal Register Volume 69, Number 217 (Wednesday, November 10, 2004)]
[Notices]
[Page 65229]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-25104]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 28, 2004, Guilford 
Pharmaceuticals, Inc., 6611 Tributary Street, Baltimore, Maryland 
21224, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of Cocaine 
(9041), a basic class of controlled substance in Schedule II.
    The company plans to manufacture a cocaine derivative to be used as 
an intermediate for the production of Dopascan Injection. Cocaine 
derivatives are a Schedule II controlled substance in the cocaine basic 
class.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
Office of Liaison and Policy (ODLR) and must be filed no later than 
January 10, 2005.

    Dated: November 1, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-25104 Filed 11-9-04; 8:45 am]
BILLING CODE 4410-09-P